Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07467772 · ClinicalTrials.gov registry record · Phase 2
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT07467772 is a Phase 2 study that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 30 participants.
The verdict
NCT07467772, a Phase 2 study, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is to evaluate the efficacy and safety of elacestrant, in participants with advanced estrogen receptor (ER)-positive uterine sarcomas. The name of the study drug involved in this research study is: -Elacestrant (a type of selective estrogen receptor degrader)
Interventions
- DRUG Elacestrant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-03-25 |
| Est. Completion | 2028-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07467772
The ClinicalTrials.gov registry entry for NCT07467772 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Elacestrant is the first listed.
NCT07467772 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07467772 about?
NCT07467772 is a clinical study titled "Ph 2 Elacestrant in ER Positive Uterine Sarcomas". This study is to evaluate the efficacy and safety of elacestrant, in participants with advanced estrogen receptor (ER)-positive uterine sarcomas. The name of the study drug involved in this research study is: -Elacestrant (a type of selective estrogen receptor degrader)
What is the current status of trial NCT07467772?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-03-25. Estimated completion is 2028-04.
What interventions are being tested in trial NCT07467772?
The interventions under investigation include: Elacestrant (DRUG).
Who is sponsoring clinical trial NCT07467772?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.